AVX 001 (AVX-001; AKH-217; FP-025; AKH217; FP025; AVX001) is a small molecule compound that targets the group IVa phospholipase A2 (GIVaPLA2) enzyme and is being developed by Coegin Pharma (formerly Avexxin AS). AVX-001 is a cytosolic phospholipase A2 (cPLA2) inhibitor potentially for the treatment of psoriasis.

纯度：≥98%

CAS：300553-18-8